DAB486interleukin-2

Drug Profile

DAB486interleukin-2

Alternative Names: Interleukin-2 fusion toxin (DAB486)

Latest Information Update: 13 Dec 1995

Price : $50

At a glance

  • Originator Seragen
  • Developer Eli Lilly; Seragen
  • Class Antihyperglycaemics; Antineoplastics; Antirheumatics; Antivirals
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued HIV infections; Inflammatory bowel diseases; Kaposi's sarcoma; Leukaemia; Lymphoma; Multiple sclerosis; Rheumatoid arthritis; Transplant rejection; Type 1 diabetes mellitus

Most Recent Events

  • 13 Dec 1995 Ajinomoto's license has been discontinued
  • 23 Aug 1995 Discontinued-II for HIV infections treatment in USA (IV)
  • 23 Aug 1995 Discontinued-Preclinical for Transplant rejection in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top